Elliot Hershberg

The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

Elliot Hershberg, Lada Nuzhna, Jorge, Erik

Industry leaders analyze a critical bottleneck in biotech where rising R&D costs, regulatory stringency, and a lack of U.S. first-in-human trials have created an environment where innovation is stifled by China's accelerated approval models. While AI is projected to reshape drug discovery by targeting previously undruggable molecules and solving efficacy failures, experts warn that current applications remain misaligned with the primary cost drivers of clinical development. The future of the sector depends on shifting from single-molecule breakthroughs to multi-modal platforms that address aging and leverage new technologies to restore the "invention" advantage against global competitors.